EFFICIENCY OF SPIOLTO RESPIMAT AND ITS INFLUENCE ON PULMONARY HYPERTENSION IN PATIENTS WITH CHRONIC OBSTRUCTIVE LUNG DISEASE
In chronic obstructive pulmonary disease (COPD), one of the most important consequences of bronchial obstruction is the formation of pulmonary hypertension (РH) and chronic pulmonary heart. At present, the question of the effect of the Spiloto Respimat preparation on hemodynamics in the pulmonary artery basins has not been sufficiently studied. The purpose of this work is to study the effect of prolonged spin-relaxation on РH in COPD patients with prolonged use. 30 patients with the 3rd stage of РH were examined on the background of the main therapy with an inhalation drug with 2 doses once a day within 24 weeks. Using the scales (expressed cough, sputum, dyspnea, auscultatory changes in the lungs), the clinical status of the patients was assessed, ECG, lung radiography, spirometry, echocardiography, and quality of life evaluation were performed. Against the background of the 24-weeks treatment, the main symptoms of the disease decreased from 7.5 + 0.3 to 1.6 + 0.3 (p <0.05), a decrease in the mean pulmonary artery pressure from 32.4 + 0.8 Up to 23.3 ± 1.2 mm Hg. The quality of life of patients has improved on scales reflecting physical and mental health. Spiolo Respimat, as a variant of a long bronchodilation therapy, leads to a significant reduction in the pulmonary artery pressure and can be used in the treatment of РH in with patients COPD.
Obolonkova NI, Maslennikov AA. Vliyanie Spiolto respimat na legochnuyu gipertenziyu u bol'nykh khronicheskoy obstruktivnoy bolezn'yu legkikh [Efficiency of Spiolto Respimat and its influence on pulmonary hypertension in patients with chronic obstructive lung disease] // Research Result. Medicine and Pharmacy // Research Result. Medicine and Pharmacy. 2017;3(2):3-8.
https://doi.org/10.18413/2313-8955-2017-3-2-3-8
While nobody left any comments to this publication.
You can be first.
1. Efremova O.A., Khodosh E.M., Efimenko E.V. Diagnostic signs for a probabilistic assessment of the risk of exacerbations of chronic obstructive pulmonary disease. Belgorod State University Scientific Bulletin. Series: Medicine. Pharmacy. 2016. Vol. 33. 5 (226). Pp. 15-20. Russian.
2. Correia L.L., Lebedev T.Yu., Efremova O.A., Proschaev K.I., Litovchenko E.S. The problem of polymorbidity in combination with chronic obstructive pulmonary disease and certain cardiovascular diseases. Belgorod State University Scientific Bulletin. Series: Medicine. Pharmacy. 2013. 21. № 4 (147). Pp. 12-17. Russian.
3. Obolonkova N.I. The influence of immunocorrection with the use of thymalin on the effectiveness of complex treatment of patients with chronic obstructive pulmonary disease complicated by chronic pulmonary heart: the dissertation ... Candidate of Medical Sciences: Avtoref. dis. … с-ta med. nauk. Astrakhan, 2006. 100 p. Russian.
4. Khodosh E.M., Efremova O.A. Classification of COPD in the aspect of GOLD (2007, 2011-2014): from stage to group membership. Belgorod State University Scientific Bulletin. Series: Medicine. Pharmacy. 2015. 16 (213). Issue 31. Pp. 5-11. Russian.
5. Khmelkova M.A. Pulmonary hypertension in patients with chronic obstructive pulmonary disease and the possibility of its medication correction: Avtoref. dis. … c-ta med. nauk. M., 2005. 121 p. Russian.
6. Chuchalin A.G., Avdeev S.N., Aisanov Z.R., Belevsky A.S., Leschenko I.V., Meshcheryakova N.N., Ovcharenko S.I., Shmelev E.I. Federal Clinical Recommendations for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease. Pulmonology. 2014. (3). Pp. 15-54. Russian.
7. Calverley P.M., Anderson J.A., Celli B. TORCH investigators. Salmeterol and fluticasone protionate and survival in COPD. N. Engl. J. Med. 2007. 356. Pp. 775-789.
8. Celli B.R., Barnes P.J. Exacerbations of COPD. Eur. Respir. J. 2007. 29. Pp. 1224-1238.
9. Global Strategy for the Diagnosis, Management, and Prevention of COPD. Scientific information and recommendations for COPD programs. Updated 2013. URL: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013Feb13.pdf (date of access: January 10, 2017)
10. Seemungal T.A.R., Donaldson G.C., Paul E.A. et al. Effect of exacerbation on quality of life in patients with COPD. Am. J. Respir. Crit. Care Med. 1998. 151. Pp. 1418-1422.
11. Soler-Cataluna J.J., Martinez-Garcia M.A., Roman S.P. et al. Severe acute exacerbations and mortality in patients with COPD. Thorax. 2005. 60. 925-931.
12. Zielinski J., MacNee W., Wedzicha J. et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch. Chest Dis. 1997. 52. Pp. 43-47.